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Résumé en
anglais
Angiogenesis plays a pivotal role in tumorigenesis and also contributes to the
pathogenesis of hematologic malignancies. A number of plant compounds have
shown efficacy in preclinical and clinical studies and some of them possess an anti-
angiogenic activity. Our present findings report anti-angiogenic activities of
ethoxyfagaronine (etxfag), a synthetic derivative of fagaronine. Once determined the
non-cytotoxic concentration of etxfag, we showed that the drug inhibits VEGF-
induced angiogenesis in a Matrigel™ plug assay and suppresses ex vivo sprouting
from VEGF-treated aortic rings. Each feature leading to neovascularization was then
investigated and results demonstrate that etxfag prevents VEGF-induced migration
and tube formation in human umbilical vein endothelial cells (HUVEC). Moreover,
etxfag also suppresses VEGF-induced VEGFR-2 phosphorylation and inhibits FAK
phosphorylation at Y-861 as well as focal adhesion complex turnover. Beside these
effects, etxfag modifies MT1-MMP localization at the endothelial cell membrane.
Finally, immunoprecipitation assay revealed that etxfag decreases VEGF binding to
VEGFR-2. As we previously reported that etxfag is able to prevent leukemic cell
invasiveness and adhesion to fibronectin, all together our data collectively support
the anti-angiogenic activities of etxfag which could represent an additional approach
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